
The acquisition brings Gallant’s experimental stem cell treatments for feline chronic gingivostomatitis and osteoarthritis in dogs and cats into Dechra’s portfolio.
Check out this week’s highlights.
With summer officially here and COVID-19 restrictions loosening across the nation, we will continue to keep you updated with our latest coverage of the veterinary industry.
Here are this week’s highlights:
Stay tuned on our social media pages and on dvm360.com for more veterinary news.





